Company intelligence / Profile preview

Chengdu Kangnuoxing Biopharma, Inc.

Chengdu, Sichuan Sheng, Chinaen.cnkh.com ↗

Ownership: Private
Employees: ~900
Development stage: Commercial

Overview

Stapokibart (CM310), an anti–IL‑4Rα monoclonal antibody developed by the company, has been approved in China for chronic rhinosinusitis with nasal polyps. The company is also running Phase III trials for atopic dermatitis and nodular prurigo. Additional assets are in earlier clinical or preclinical development targeting autoimmune diseases and oncology.

Therapeutic areas: OncologyDermatologyImmunologyNeurology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesAntibody-drug conjugates (ADCs)Small nucleic acids
Industry: Biotech

Drug pipeline

1 asset

Spectrobab

Preclinical

Partnerships

Collaborations with other pharmaceutical & biotech companies via parent company platforms; specifics not detailed.

Beyond the preview

Go deeper on Chengdu Kangnuoxing Biopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Kangnuoxing Biopharma, Inc..

Explore the full profile